Want to see SE:EXPRS2 full AI Analyst Report?
EXPRS2 Stock Chart & Stats
kr17.10
-kr1.20(-4.51%)
At close: 4:00 PM EST
kr17.10
-kr1.20(-4.51%)
Day’s Range― - ―
52-Week Rangekr1.22 - kr9.20
Previous CloseN/A
Volume135.00
Average Volume (3M)19.88K
Market Cap
kr34.67M
Enterprise Valuekr4.08
Total Cash (Recent Filing)kr21.84M
Total Debt (Recent Filing)kr1.25M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.33
Shares Outstanding23,748,983
10 Day Avg. Volume26,629
30 Day Avg. Volume19,883
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.27
Price to Sales (P/S)12.37
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.64
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt relative to equity reduces near-term refinancing pressure and gives management flexibility to fund R&D or pursue partnerships without immediate solvency risk. This structural balance-sheet strength lengthens runway relative to highly leveraged peers.
Proprietary Expression PlatformOwning a specialized insect-cell expression technology is a durable competitive advantage in biotech services: it addresses a structural need for difficult-to-express proteins, supports premium service demand, and underpins licensing or long-term collaboration opportunities.
Multiple Revenue ChannelsA multi-pronged monetization model (services, licensing, collaborations) provides durable optionality: service fees supply near-term revenue, while licensing and partnerships can scale with limited incremental capex and create milestone/royalty upside over time.
Bears Say
Persistent Cash BurnSustained heavy operating cash outflows indicate the business is not self-funding; this structural cash burn necessitates continued external financing that can dilute shareholders or constrain strategic choices and raises medium-term runway risk.
Small And Declining RevenueA low and shrinking revenue base limits ability to scale fixed R&D and production costs into positive margins; until top-line stability or growth is achieved, operating leverage cannot be realized and margins will likely remain under pressure.
Negative Gross Profit And Large LossesStructurally negative gross margins indicate the current cost structure or pricing model fails to cover direct production costs. Persistent operating losses signal the business model has yet to reach sustainable unit economics, increasing reliance on external capital.
EXPRS2 FAQ
What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?
ExpreS2ion Biotech Holding AB lowest stock price was kr1.22 and its highest was kr9.20 in the past 12 months.
What is ExpreS2ion Biotech Holding AB’s market cap?
ExpreS2ion Biotech Holding AB’s market cap is kr34.67M.
When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?
ExpreS2ion Biotech Holding AB’s upcoming earnings report date is Aug 20, 2026 which is in 8 days.
How were ExpreS2ion Biotech Holding AB’s earnings last quarter?
ExpreS2ion Biotech Holding AB released its earnings results on May 28, 2026. The company reported -kr0.97 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ExpreS2ion Biotech Holding AB overvalued?
According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued.
Does ExpreS2ion Biotech Holding AB pay dividends?
ExpreS2ion Biotech Holding AB does not currently pay dividends.
What is ExpreS2ion Biotech Holding AB’s EPS estimate?
ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ExpreS2ion Biotech Holding AB have?
ExpreS2ion Biotech Holding AB has 23,748,983 shares outstanding.
What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?
ExpreS2ion Biotech Holding AB reported an EPS of -kr0.97 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.301%.
Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?
Currently, no hedge funds are holding shares in SE:EXPRS2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ExpreS2ion Biotech Holding AB
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.